TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06683417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation Aid
Description: The tablet-based VestAid system was developed to repair, restore and maintain vestibular-ocular function that is impaired in patients post-mTBI.~Each participant\&amp;#39;s treating physical therapist will develop their own personalized exercise prescription. The physical therapist will be asked to recommend that the patients complete a home exercise program at least 2-3 times per day for 6 weeks. The exercise prescription will be placed on the VestAid by the physical therapist for the patient to follow. The patient is not able to modify the exercise, only the physical therapist can modify the exercises. Exercises will be modified based on patient\&amp;#39;s response and symptom reports. The physical therapist and study coordinator will receive an alert on the VestAid online dashboard if the patient\&amp;#39;s symptoms are greater than or equal to 8/10.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care vestibular rehabilitation
Description: Vestibular rehabilitation to include gaze stabilization exercises, optokinetic training, smooth pursuits and saccades
Study: NCT06683885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone
Description: For non GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Obutinib, 150mg, QD, P.O.; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Obutinib maintain treatment for 6 months. Obutinib, 150mg, QD, P.O. After 6 cycles of initial treatment, the efficacy was evaluated.~For GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Decitabine, 10mg, QD，D1-5, ivgtt; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Decitabine maintenance treatment for 4 cycles, 21 days per cycle. Decitabine, 10mg, QD，D1-5, ivgtt. Evaluate the efficacy after 6 cycles of treatment.
Study: NCT06683495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: For mirror therapy, a 50×40 cm mirror will be used
Study: NCT06683716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training in presence of the instructor
Description: The instructor gives the trainee instructions for the examination while he/she is present in the examination room.
Study: NCT05458375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal cream
Description: Insert pea-sized amount of vaginal estradiol cream into vagina nightly for first two weeks and then twice weekly thereafter.
Study: NCT06683716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedically training by an instructor
Description: The trainer gives instructions to the trainee through a telemedical connection to the examiner using SmartGlasses
Study: NCT05618119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]MC225
Description: \[18F\]MC225 PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]MC225
Description: \[18F\]MC225 PET scan
Study: NCT06126796

Intervention type: DIAGNOSTIC_TEST
Intervention: CxBladder Monitor
Description: CxBladder Monitor (CxbM) is an FDA-approved genomic biomarker test specifically designed for patients undergoing surveillance for NMIBC. The non-invasive urine test quantifies 5 measured biomarker genes (MDK, HOXA13, CDC2 (CDK1), IGFBP5, CXCR2) and incorporates this information into an algorithm to detect the presence or absence of bladder cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: CxBladder Monitor
Description: CxBladder Monitor (CxbM) is an FDA-approved genomic biomarker test specifically designed for patients undergoing surveillance for NMIBC. The non-invasive urine test quantifies 5 measured biomarker genes (MDK, HOXA13, CDC2 (CDK1), IGFBP5, CXCR2) and incorporates this information into an algorithm to detect the presence or absence of bladder cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cystoscopy
Description: Cystoscopy is the most common way surveillance has been performed for NMIBC. Cystoscopy is a procedure that allows your doctor to examine the lining of your bladder and the tube that carries urine out of your body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into your bladder.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cystoscopy
Description: Cystoscopy is the most common way surveillance has been performed for NMIBC. Cystoscopy is a procedure that allows your doctor to examine the lining of your bladder and the tube that carries urine out of your body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into your bladder.
Study: NCT05544513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate 3 days week
Description: Participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate daily
Description: Participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate higher concentration
Description: Participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
Study: NCT06355310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants will take an identical appearing oral tablet with zero active ingredient.
Study: NCT05305105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Dosing at the first session will be 15mg. For the second session participants will either remain at the initial dose, or increase to 25mg.
Study: NCT04183413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSD
Description: This intervention consist of three Differentiated Service Delivery Models in which stable clients can be enrolled. The fast-track model gives preferential treatment to enrolled clients. Clients arrive at clinics, usually early in the morning, and can see the nurse as well as collect their medication without queuing. This model mainly targets the working population. The facility-based treatment clubs consist of bimonthly meetings where clients meet in groups of approximately 20 members. They receive health counselling, risk factor screening and medication prescription. This model mainly targets clients living close to the facility. The community advisory groups consist of groups of up to six clients. Groups are equipped with a point of care blood pressure and blood glucose measurement devices. They take turns in collecting the medication for the entire group and meet on a monthly basis. This model targets clients in hard-to-reach areas.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDP
Description: Community Distribution Points are set up on a monthly basis in communities linked to the clinic. Healthcare staff sets up a temporary point of contact where clients can obtain screening for diabetes and hypertension, health counselling, referral to primary or tertiary facilities, and medication.
Study: NCT06495138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StableEyes
Description: Gaze stabilization exercises using the StableEyes device for the incremental vestibular-ocular reflex adaptation approach.~The StableEyes device consists of a lightweight head unit with a 9-dimension inertial measurement unit and electrostatic micro-mirror that dynamically controls the 2-dimensional position of a 1-milliwatt red laser projected on a wall 1 meter in front of the subject. StableEyes is controlled via a lightweight control unit with a touchscreen interface tethered by cable to the head unit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StableEyes
Description: Gaze stabilization exercises using the StableEyes device for the incremental vestibular-ocular reflex adaptation approach.~The StableEyes device consists of a lightweight head unit with a 9-dimension inertial measurement unit and electrostatic micro-mirror that dynamically controls the 2-dimensional position of a 1-milliwatt red laser projected on a wall 1 meter in front of the subject. StableEyes is controlled via a lightweight control unit with a touchscreen interface tethered by cable to the head unit.
Study: NCT05779033

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: scapular stabilization exercises
Description: scapular stabilization exercises 3 times per week for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: scapular stabilization exercises
Description: scapular stabilization exercises 3 times per week for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: scapular stabilization exercises
Description: scapular stabilization exercises 3 times per week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: Ultrasound 3 times per week for 4 weeks.continuous US operated at a frequency of 1 MHz and at an intensity of 1.5 W/cm2 for 5 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape
Description: Kinesiotape 3 times per week for 4 weeks. We will apply taping to two muscles (deltoideus and supraspinatus). A Y' tape was placed over the deltoid muscle using the muscle stimulation (KT strip arms were located by stretching slightly by 15%-25%) and mechanical correction techniques (KT strip arms were located with maximal stretching). Another Y tape was placed over the supraspinatus muscle using the muscle inhibition technique (the starting point of the tape was attached to the sub acromial-greater tubercle with submaximal (75%) stretching and without stretching on strip arms).
Study: NCT05708443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LL group
Description: The program will include daily sessions of 90 minutes, for a total of 14 sessions, consisting of:~1. 60 minutes on a stationary bike for the lower limbs (2 sessions per day of 30 minutes) at moderate-high intensity;~2. 30 minutes of strengthening exercises for upper limbs (biceps, pectoral, latissimus dorsi) and lower limbs (quadriceps, gluteus and hamstrings) performed free body or with the aid of weights.~All sessions will be supervised by a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L+UL group
Description: These patients will attend a rehabilitation program with daily sessions of 90 minutes, for a total of 14 sessions, consisting of:~1. 30 minutes on a stationary bike for the lower limbs (1 session of 30 minutes per day) at moderate-high intensity;~2. 30 minutes with arm-ergometer (1 daily session of 30 minutes) at moderate-high intensity;~3. 30 minutes of strengthening exercises for upper limbs (biceps, pectoral, latissimus dorsi) and lower limbs (quadriceps, gluteus and hamstrings) performed free body or with the aid of weights.~All sessions will be supervised by a physiotherapist.
Study: NCT06407765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual task training
Description: Dual task training incorporates both cognitive and motor tasks. Tasks like walking and asking the patient to point towards objects, collect start from the objects hanging above the patient and asking the patient to name the objects shown to him/her. This treatment will be given for 4 weeks, 4 times a week for 40 minutes. Each task is done for 7 minutes with a 3 minutes break in between.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training with backward walking
Description: This group will get both dual task training and backward walking. For dual task training same protocol as active comparator is followed. For backward walking; the patient is firstly asked to walk backward with complete physiotherapist assistance. Secondly, the patient is asked to walk for 15 m through the treatment room's hallway while holding a safety bar with the hand on the unaffected side. Third, without using a safety bar, the participants were urged to walk freely. Lastly, the participants tried to walk backwards at a reasonable pace while progressively increasing their distance travelled and speed. This treatment will be given for 4 weeks, 4 times a week for 40 minutes. Each task is done for 7 minutes with a 3 minutes break in between.
Study: NCT05314322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation with high frequency
Description: Deep brain stimulation implanted at the patients' Substantia Nigra

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation with low frequency
Description: Deep brain stimulation implanted at the patients' Substantia Nigra
Study: NCT04657224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64264681
Description: JNJ-64264681 capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64264681
Description: JNJ-64264681 capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67856633
Description: JNJ-67856633 capsules or tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67856633
Description: JNJ-67856633 capsules or tablets will be administered orally.
Study: NCT05497427

Intervention type: DEVICE
Intervention: BrainCheck Assessment
Description: A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance

Intervention type: DEVICE
Intervention: BrainCheck Assessment
Description: A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance

Intervention type: DEVICE
Intervention: BrainCheck Assessment
Description: A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
Study: NCT06001333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: Fecal microbiota transplantation will be conducted on patients using donor stool (frozen or capsulized stool) from a stool bank.
Study: NCT04566302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SECM Skin Imaging
Description: Consented Participants will be asked to allow their forearm to be imaged by the dermatoscope on the same skin/lesions as a control comparison. We will be trying to image pigmented skin/lesions present on the forearm. This will be followed by imaging using the SECM Skin imaging device
Study: NCT06144632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL STSF Bi- Directional Navigation Catheter
Description: THERMOCOOL STSF will be used in conjunction with TRUPULSE Generator to give pulsed field (PF) ablation or radiofrequency (RF) ablation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUPULSE Generator
Description: TRUPULSE Generator will be used to deliver PF/RF ablation.
Study: NCT05647863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Cognitive and Sensory Treatment (F-CaST)
Description: F-CaST, a client-centered care, is a functional cognitive sensory intervention focusing on improving Executive Function (EF) and sensory modulation impairments using a modification of the Functional and Cognitive Occupational Therapy Treatment.
Study: NCT04816149

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Standard Suicide Intervention
Description: Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment for Relationships and Safety Together (TR&ST)
Description: TR\&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
Study: NCT06112730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pulmonnary rehabilitation
Description: Undergo routine pulmonary rehabilitation without dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation intervention
Description: Receive personalized dietary guidelines based on indirect calorimetry assessment
Study: NCT06499285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KER-050
Description: KER-050 administered subcutaneously every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously every 4 weeks
Study: NCT06427122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMD Protocol for Urge
Description: During the EMD-U sessions, the patient is asked to focus on the spot on his/her skin where the urge to scratch is highest. The patient is asked to rate the level of urge to scratch this spot on a 10-point scale and to imagine that they scratch this spot as they would like. At the same time eye movements are offered for 30 seconds. This procedure is repeated until the level of urge to scratch has become nihil. This procedure is repeated for all other skin parts where the patient experiences an urge to scratch, until there are no skin parts left. As a homework assignment straight after the first session, the patient is instructed and encouraged to practice the same intervention at home. The two EMD-U sessions and two phone calls, take place in the first three weeks of the study. In the five following weeks, patients are phoned twice to ask for their experiences with the practicing at home.
Study: NCT06515236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic Treatment Assessment for Youth (STAY)
Description: Culturally tailored measurement based care
Study: NCT06427122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual
Description: Patients in the control group receive care as usual (CAU), which is the standard care of the dermatologist. In addition to completing the questionnaires at T0, 1, 2, 3, and 4 these patients are not offered any additional treatment or support aimed at their scratching behaviour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care as Usual
Description: Patients in the control group receive care as usual (CAU), which is the standard care of the dermatologist. In addition to completing the questionnaires at T0, 1, 2, 3, and 4 these patients are not offered any additional treatment or support aimed at their scratching behaviour.
Study: NCT06637423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Intravesical administration
Study: NCT05047250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
Study: NCT05302505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation-based training
Description: Based-simulation training for nurses in a simulation center : puncture of arteriovenous fistula and utilization of echograph and conversational hypnosis
Study: NCT04286126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active bilateral DMPFC
Description: Participants in this arm will receive rTMS to bilateral DMPFC. The DMPFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 100% of resting motor threshold (RMT).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active right-sided OFC
Description: Participants in this arm will receive rTMS to the right OFC. The right OFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 110% of resting motor threshold (RMT).
Study: NCT05003050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Holistic natural therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pranic Healing
Description: Energy therapy
Study: NCT05300802

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hcl 100 Mcg/mL Inj
Description: 1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hcl 100 Mcg/mL Inj
Description: 0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.
Study: NCT06515236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Measurement Based Care As Usual
Description: Measurement based care as usual
Study: NCT06065813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 200 mg Toripalimab intravenously every 3 weeks 3 doses of Toripalimab before operation 14 doses of Toripalimab 30 days after operation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional segmental radiotherapy
Description: the does of radiation will be 40-45Gy. The day of the first dose of Toripalimab and the first day of radiation must be the same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: opreation
Description: The operable patients will accept radical operated in 28-42 days after the third dose of Toripalimab